Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer
about
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Therapeutic Considerations in Treating HER2-Positive Metastatic Breast CancerA phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancerEmerging strategies for treating brain metastases from breast cancer.Challenges and perspective of drug repurposing strategies in early phase clinical trials.Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain MicroenvironmentCombination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review.Treatment of Brain Metastases.Risk factors and survival outcome in cerebral metastatic breast cancer.
P2860
Q30399006-94B6693C-4C65-4F9F-A1E8-C3CE5CD10E20Q33787355-E4A6DBBB-A197-4154-93FC-E851C9127FCCQ34268618-817DCA5F-ABE3-4CB1-BB25-E57053511C2EQ34978404-DF0D4429-DAAE-4459-BE0B-E7C0BB794B41Q35075446-CF1451B9-E777-4616-84B8-CE0C2CB30AEBQ35863063-4183F1BD-75AD-49B4-BE6A-00678785ED11Q36887659-CF424A01-4D45-43C1-B8D8-469CA31AD0C0Q37653981-D2EB3F3D-4098-477B-94B7-9DB130EF8269Q48162978-99163409-AC43-44C8-BA12-F8FDA25B57EFQ53827061-7028FFD5-AF9B-4137-817B-E4D7A3484100Q54379038-A645EF8C-6863-42BA-B1D2-6B2F3C2D3B67
P2860
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dual HER2 inhibition in combin ...... ed HER2-positive breast cancer
@en
Dual HER2 inhibition in combin ...... d HER2-positive breast cancer.
@nl
type
label
Dual HER2 inhibition in combin ...... ed HER2-positive breast cancer
@en
Dual HER2 inhibition in combin ...... d HER2-positive breast cancer.
@nl
prefLabel
Dual HER2 inhibition in combin ...... ed HER2-positive breast cancer
@en
Dual HER2 inhibition in combin ...... d HER2-positive breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Dual HER2 inhibition in combin ...... ed HER2-positive breast cancer
@en
P2093
C C Bastida
G S Falchook
J J Wheler
R Kurzrock
S L Moulder
P2860
P304
P356
10.1093/ANNONC/MDT395
P577
2013-10-24T00:00:00Z